The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience
- 19 January 2018
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 47 (6) , 838-844
Abstract
Summary: Background: The combination of ledipasvir plus sofosbuvir was recently approved for treatment of adolescent (12‐17 years) HCV genotype 1, 4, 5 & 6 patients. However, few clinical trials have been performed in genotype 1 patients.Aim: To investigate the effectiveness and safety of ledipasvir plus sofosbuvir in chronic HCV adolescent patients with genotype 4 in the real world.Methods: This prospective multicentre (six centres) open‐label study included 144 adolescent chronic HCV patients with genotype 4 (mean age 14 ± 2, 69% males). All patients received a combination tablet containing 400 mg sofosbuvir and 90 mg ledipasvir once daily for 12 weeks. Laboratory and virological markers were evaluated at baseline, week 4, week 8 and week 12 (EOT), and 12 weeks after end of treatment (SVR12).Results: SVR12 was observed in 142/144 patients (99%). The relapsers occurred in previous naïve patients (n = 2/128, 2%), while the experienced patients showed 100% SVR12. SVR12 was 98% in F0/F1 patients in comparison to 100% in F2 patients (P = 0.552). No serious side effects were observed, nor was treatment discontinuation or death. Headache was the most common side effect in all patients (20%). In experienced patients, pruritus (31%, P = 0.007), diarrhoea (44%, P < 0.001) and skin rash (19%, P = 0.002) were higher than in naïve patients.Conclusions: A ledipasvir plus sofosbuvir regimen is well tolerated and effective, and can be used safely in treating adolescent patients with chronic hepatitis C genotype 4.Keywords
This publication has 30 references indexed in Scilit:
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis CGastroenterology, 2011
- Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort studyJournal of Hepatology, 2010
- Hepatocellular Carcinoma in 2 Young Adolescents With Chronic Hepatitis CJournal of Pediatric Gastroenterology and Nutrition, 2009
- Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-AnalysisGastroenterology, 2008
- Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C TrialHepatology, 2008
- Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence dataInternational Journal of Epidemiology, 2004
- The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in EgyptThe Lancet, 2000